MMP-8 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human neutrophil collagenase (MMP-8, UniProt P22894) expressed in HEK293 cells. Suited for fibrillar collagen substrate assays, inhibitor IC50 determination, and antibody validation.
Expression system
HEK293
Cat. #
REC-MMP8

In stock

SKU
REC-MMP8
$498.00

Target Overview

MMP-8 (Matrix metalloproteinase-8; neutrophil collagenase; UniProt P22894) is a zinc-dependent endopeptidase classified under EC 3.4.24.34. The full-length human sequence spans 467 amino acids, encompassing a signal peptide, propeptide, catalytic domain bearing the conserved HEXXHXXGXXH zinc-binding motif, and a C-terminal hemopexin-like domain. The mature, processed form is the predominant species active against fibrillar substrates. Natively abundant in the cytoplasmic granules of polymorphonuclear leukocytes, MMP-8 is one of the primary collagenases capable of cleaving the triple helix of type I, II, and III fibrillar collagens at the canonical Gly-Ile/Leu bond, initiating irreversible collagen degradation. This recombinant is produced in HEK293 cells, which provide mammalian post-translational processing and glycosylation patterns more representative of the endogenous protein than bacterial or insect-cell systems — a consideration when characterising inhibitor binding kinetics or substrate-recognition properties that may be sensitive to folding or glycan context. Researchers use this reagent in several experimental contexts: (1) direct measurement of collagenase activity against fluorogenic or synthetic peptide substrates; (2) determination of inhibitor potency (IC50/Ki) for small-molecule or peptidic MMP-8 inhibitors; (3) as a positive-control antigen for antibody validation by Western blot or ELISA; and (4) as a defined enzyme source in substrate-identification proteomics workflows. Researchers requiring a matched antibody for co-validation can pair this recombinant with the Triple Point Biologics MMP-8 antibody (SKU: RP-MMP8), which has been validated for Western blot against human MMP-8, with predicted cross-reactivity to mouse, rat, monkey, and dog.

Background

MMP-8 is a member of the collagenase subgroup of the matrix metalloproteinase family, which collectively coordinate extracellular matrix remodelling across connective tissue homeostasis, wound healing, and inflammatory responses. First characterised in polymorphonuclear leukocytes (PMNLs) — hence the alternative designation PMNL collagenase — MMP-8 is stored preformed in specific (secondary) and gelatinase (tertiary) granules and rapidly released upon neutrophil activation, positioning it as an early effector of matrix degradation at inflammatory sites. The primary substrates of MMP-8 are the fibrillar collagens type I, II, and III, which together constitute the structural scaffold of skin, tendon, bone, cartilage, and periodontal ligament. Cleavage by MMP-8 at the specific three-quarter/one-quarter scissile bond produces collagen fragments that are subsequently denatured and processed by gelatinases. Beyond the major collagen substrates, MMP-8 has been shown in published research to act on a range of extracellular and pericellular substrates, contributing to modulation of chemokine gradients and inflammatory signalling cascades. In the research literature, MMP-8 has been studied as a candidate biomarker across several disease-relevant contexts. Alhelfi et al. (2026, PMID 42287034) measured salivary MMP-8 levels in a case-control study of periodontitis and nephrolithiasis, illustrating the enzyme's utility as a soluble biomarker in inflammatory oral disease research. Similarly, Mainas et al. (2026, PMID 42269677) quantified MMP-8 in gingival crevicular fluid as part of a randomised pilot trial examining the inflammatory response following periodontal treatment, underscoring its role as a local tissue-remodelling readout. Additional published work has investigated MMP8 in the context of tumour biology, with Borikun (2026, PMID 42290557) reporting stress-induced methylation changes at the Mmp8 locus in a rat carcinoma model — a finding relevant to researchers using recombinant MMP-8 to characterise epigenetic or transcriptional control of enzyme activity. MMP-8 has further been studied as a transcriptomic feature in peripheral blood during septic shock (Li et al., 2026, PMID 42266692) and as part of integrated inflammatory signature models in preterm labour research (Hong et al., 2026, PMID 42327783). For in vitro research, recombinant MMP-8 expressed in a mammalian system provides a defined, active enzyme source to dissect substrate preferences, measure inhibitor potency, and serve as a reliable positive control in immunodetection workflows — applications that are difficult to standardise with cell-conditioned media or tissue extracts.

Applications

  • Collagenase activity assay against type I, II, or III fibrillar collagen substrates
  • Fluorogenic peptide substrate cleavage assay (e.g., Mca-KPLGL-Dpa substrates) for kinetic parameter determination
  • Inhibitor IC50 and Ki determination for small-molecule or peptidic MMP-8 inhibitors
  • Positive-control antigen for Western blot validation of anti-MMP-8 antibodies (pairs with RP-MMP8)
  • ELISA standard or spike-in control for quantification of MMP-8 in biological fluids
  • Substrate identification by mass spectrometry-based degradomics (TAILS or similar)
  • Enzyme source for selectivity profiling across the MMP family in inhibitor screening panels
  • Recombinant antigen for immunisation or antibody specificity testing in research workflows

References

  1. Hong S et al. Vaginal dysbiosis and inflammatory signatures in preterm labor: an integrated model for predicting preterm birth. Front Immunol. 2026. doi:10.3389/fimmu.2026.1809046. PMID: 42327783.
  2. Borikun T. Stress-Induced Changes in the Methylation Status of Mmp1 and Mmp8 Genes in Tumor Tissue of Rats with Guerin Carcinoma. Exp Oncol. 2026. doi:10.15407/exp-oncology.2026.01.046. PMID: 42290557.
  3. Alhelfi NM et al. Salivary Inflammatory Biomarkers in Males With Nephrolithiasis Correlate With Periodontal Status: A Case-Control Study. Biomed Res Int. 2026. doi:10.1155/bmri/1619093. PMID: 42287034.
  4. Mainas G et al. A Fasting-Mimicking Diet Affects the Inflammatory Response Following Periodontal Treatment: A Multi-centre Feasibility Randomised Controlled Pilot Trial. J Clin Periodontol. 2026. doi:10.1111/jcpe.70139. PMID: 42269677.
  5. Li L et al. Multi-cohort transcriptomics integration for building and validating a diagnostic model of peripheral blood septic shock. Front Immunol. 2026. doi:10.3389/fimmu.2026.1768866. PMID: 42266692.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What molecular weight band should I expect for recombinant MMP-8 on SDS-PAGE or Western blot?

The full-length human MMP-8 precursor (467 aa, UniProt P22894) has a predicted MW of ~53 kDa, but the HEK293-expressed recombinant runs at approximately 55–58 kDa under denaturing conditions due to N-linked glycosylation. If you are running the mature, processed form (propeptide removed), expect the band closer to 48–50 kDa. Under reducing conditions (+β-ME or DTT), a single band is expected; non-reducing gels may show higher-MW species from intermolecular disulfide aggregation. Purity is >95% by SDS-PAGE, so minor bands near the main species are glycoform heterogeneity, not contaminating proteins.

Is this recombinant MMP-8 the full-length proenzyme or the processed active form?

REC-MMP8 is supplied as the active enzyme — the propeptide (residues ~19–99) has been processed, exposing the catalytic domain with its HEXXHXXGXXH zinc-binding motif. The hemopexin-like C-terminal domain is retained, which is important for substrate specificity toward fibrillar collagens and for studying TIMP binding interactions. If your experiment requires the latent zymogen form for activation studies, this product is not appropriate; contact us about custom formats. The active form is the predominant species found in PMN granules and is the most physiologically relevant for collagenase activity assays.

What substrates does recombinant MMP-8 cleave, and what fluorogenic peptide should I use for an activity assay?

MMP-8 cleaves fibrillar collagens (types I, II, and III) at the canonical Gly-Ile/Leu bond, initiating triple-helix unwinding. For in vitro fluorogenic activity assays, the widely used substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂ (MMP FRET peptide I) is well-validated for MMP-8; excitation at 328 nm, emission at 393 nm. Alternatively, Mca-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Lys(Dnp)-NH₂ works for broader MMP profiling. A starting enzyme concentration of 1–5 nM in assay buffer with 5 mM CaCl₂ (included in storage buffer) and 0.05% Brij-35 at 37 °C is a practical starting point before titrating for your substrate concentration range.

What buffer conditions work best for MMP-8 collagenase activity assays, and does the storage buffer interfere?

REC-MMP8 is stored in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂. The 5 mM CaCl₂ is intentional — calcium is essential for MMP-8 stability and catalytic activity, so ensure your assay buffer is also supplemented (typically 5–10 mM CaCl₂). Glycerol at 10% can slightly reduce fluorogenic signal; dilute the enzyme at least 1:10 into assay buffer to bring glycerol to ≤1%. Zinc (1 µM ZnCl₂) in assay buffer is advisable for prolonged incubations. Avoid EDTA or EGTA entirely — chelators will inactivate the enzyme. Optimal pH is 7.4–7.6; deviations below 7.0 significantly reduce activity.

How do I determine an appropriate IC50 for an MMP-8 inhibitor using this recombinant, and what enzyme concentration should I use?

For IC50 determinations, keep enzyme concentration well below the inhibitor concentration range you intend to test — typically 1–2 nM REC-MMP8 is appropriate for tight-binding inhibitors (e.g., hydroxamates with Ki in the pM–nM range) to avoid stoichiometric artifacts. Use substrate at or below Km (≈10–20 µM for Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH₂) to approximate Ki from IC50 via Cheng-Prusoff. Because this protein is HEK293-derived with mammalian glycosylation, inhibitor binding kinetics better reflect those measured against endogenous neutrophil collagenase than bacterially expressed constructs — a meaningful consideration when translating IC50 data to cellular or in vivo models.

Can I use REC-MMP8 as a positive control for Western blot with the matched RP-MMP8 antibody?

Yes — REC-MMP8 and RP-MMP8 are designed as a matched pair for exactly this use case. Load 10–50 ng of REC-MMP8 per lane; 25 ng is a reliable starting point and should produce a clean band at ~55–58 kDa (glycosylated active form) with RP-MMP8 at standard dilutions of 1:500–1:2,000. Because RP-MMP8 is a rabbit polyclonal raised against the human MMP-8 protein, it recognizes multiple epitopes across the mature sequence, making it robust even when your sample is partially degraded. See the RP-MMP8 product page (/anti-mmp-8-rabbit-polyclonal-antibody) for full dilution and blocking conditions.

How much recombinant MMP-8 should I load for a Western blot positive control, and will it look the same as endogenous MMP-8 from cell lysates?

Load 10–50 ng per lane for a clean, unambiguous positive control band. The recombinant runs at ~55–58 kDa due to mammalian glycosylation in HEK293 cells, which closely matches the endogenous neutrophil-derived MMP-8 seen in PMN lysates or conditioned media (~55–75 kDa range depending on glycosylation state and activation status). This alignment makes REC-MMP8 a more informative positive control than bacterial constructs, which typically run lighter (aglycosylated ~48 kDa) and can mislead band-size interpretation. Pair with RP-MMP8 (SKU: RP-MMP8) for a fully validated positive control setup.

How should I handle, aliquot, and store recombinant MMP-8 to preserve activity long-term?

REC-MMP8 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl₂ and should be stored at −20 °C in single-use aliquots upon receipt. Avoid repeated freeze-thaw cycles — even two additional cycles can reduce collagenase activity by 20–30%. If you anticipate frequent use over 1–2 weeks, keep a working aliquot at 4 °C; activity is stable for up to 7 days under these conditions. Do not dilute in pure water — dilute into assay buffer containing at least 5 mM CaCl₂ and 0.05% Brij-35 to stabilize the enzyme. Carrier protein (0.1% BSA) can be added for very dilute working stocks below 10 nM.

Validation imagery coming soon

Western blot validation figures for REC-MMP8 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →